25th October 2016 – Oxford BioDynamics, an Oxford UK-based biotechnology firm, presented at The Lancet Neurology Conference at the Park Plaza Riverbank in London on 20th October 2016. The aim of the conference was to broadcast cutting-edge findings on preclinical neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and Huntington’s disease.
26 October, 2016
Researchers at the University of Bradford have discovered a way to prevent chemotherapy resistance in lung cancer by blocking a protein found in cancer cells.Suppressing this protein, called Ran-GTP, also causes cancer cells already resistant to the first-line chemotherapy treatment, gefitinib, to become re-sensitised to the drug.
06 October, 2016